| scholarly article | Q13442814 |
| P50 | author | Sin Gon Kim | Q60321492 |
| P2093 | author name string | Nam Hoon Kim | |
| Soo Heon Kwak | |||
| Min Kyong Moon | |||
| Soo Lim | |||
| Juneyoung Lee | |||
| Jun Sung Moon | |||
| Yong-Ho Lee | |||
| Ho Chan Cho | |||
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients | Q26740228 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q28262769 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| The natural history of type 2 diabetes. Implications for clinical practice | Q33752751 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor | Q34161881 | ||
| Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia | Q36108419 | ||
| beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. | Q41000321 | ||
| Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin | Q41685708 | ||
| Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. | Q44391845 | ||
| Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function | Q45124452 | ||
| Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 | ||
| Relation of glycemic control to diabetic microvascular complications in diabetes mellitus | Q70880944 | ||
| The association of glycemia and cause-specific mortality in a diabetic population | Q72855277 | ||
| Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes | Q86057577 | ||
| Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes | Q86623452 | ||
| Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial | Q88117871 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | e022448 | |
| P577 | publication date | 2018-09-24 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial | |
| P478 | volume | 8 |
Search more.